PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53
Metadata
Show full item recordAuthor
Puentes Pardo, José David; Moreno SanJuan, Sara; Casado, Jorge; Escudero Feliú, Julia; López Pérez, David; Sánchez-Uceta, Paula; González Novoa, Paula; Gálvez Peralta, Julio Juan; Carazo, Ángel; León, JosefaMateria
Colorectal cancer PARP-1 Cancer stem cells P53
Date
2023-03-01Referencia bibliográfica
Puentes-Pardo, J.D.; Moreno-SanJuan, S.; Casado, J.; Escudero-Feliu, J.; López-Pérez, D.; Sánchez-Uceta, P.; González-Novoa, P.; Gálvez, J.; Carazo, Á.; León, J. PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53. Int. J. Mol. Sci. 2023, 24, 4787. [https://doi.org/10.3390/ijms24054787]
Sponsorship
Instituto de Salud Carlos III FEDER (PI18/01947).; J.L. was supported by the Nicolás Monardes Program from the Andalusian Health Service (C-0033-2015). J.D.P.-P; J.D.P.-P. is funded by a FPU2019 fellowship (FPU190/02269) from the Ministerio de Universidades (Spain).Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a protein involved in multiple physiological
processes. Elevated PARP-1 expression has been found in several tumours, being associated with
stemness and tumorigenesis. In colorectal cancer (CRC), some controversy among studies has been
described. In this study, we analysed the expression of PARP-1 and cancer stem cell (CSC) markers
in CRC patients with different p53 status. In addition, we used an in vitro model to evaluate the
influence of PARP-1 in CSC phenotype regarding p53. In CRC patients, PARP-1 expression correlated
with the differentiation grade, but this association was only maintained for tumours harbouring
wild-type p53. Additionally, in those tumours, PARP-1 and CSC markers were positively correlated.
In mutated p53 tumours, no associations were found, but PARP-1 was an independent factor for
survival. According to our in vitro model, PARP-1 regulates CSC phenotype depending on p53 status.
PARP-1 overexpression in a wild type p53 context increases CSC markers and sphere forming ability.
By contrast, those features were reduced in mutated p53 cells. These results could implicate that
patients with elevated PARP-1 expression and wild type p53 could benefit from PARP-1 inhibition
therapies, meanwhile it could have adverse effects for those carrying mutated p53 tumours.